P-597. Amezosvatein Demonstrates Non-Inferior Immunogenicity and Superior Tolerability Head-to-Head vs Shingrix in a Phase 2 Herpes Zoster Vaccine Trial
Bibliographic record
Abstract
Abstract Background Low uptake and significant second-dose avoidance for herpes zoster (HZ) vaccination are behaviors linked to poor tolerability of the existing AS01B-adjuvanted recombinant gE herpes zoster vaccine, Shingrix, and represent an unmet medical need for a less reactogenic herpes zoster vaccine. Amezosvatein (CRV-101) is an investigational recombinant gE vaccine using a third-generation synthetic adjuvant (SLA-SE) targeting the human TLR4 receptor with improved tolerability and non-inferior immunogenicity. Humoral Immunogenicity: Anti-gE Antibody VRR and GMFR, and Anti-VZV Neutralizing Antibody GMFR Vaccine Response Rate, defined as a 4-fold rise in antibody concentration from baseline, Geometric Mean Fold-Rise (GMFR) in anti-gE ELISA from baseline, and fold rises in neutralizing antibody were identical or higher for amezosvatein Methods A randomized, observer-blind, active-controlled, multi-center Phase 2 trial of amezosvatein versus Shingrix enrolled 876 participants aged 50+. Participants received two injections of either Shingrix or amezosvatein at up to 100 μg of gE antigen with 5, 10, or 15 μg of SLA-SE. The primary endpoints of the study compared safety/tolerability and non-inferiority of immunogenicity of amezosvatein vs Shingrix. Amezosvatein demonstrates superior tolerability to Shingrix Amezosvatein demonstrated a clinically superior tolerability profile compared to Shingrix as measured by Grade 2/3 solicited local and systemic adverse events. Results Amezosvatein at 100 μg gE/15 μg SLA-SE demonstrated immunogenicity non-inferior to Shingrix at Day 84 as measured by anti-gE ELISA Geometric Mean Concentration (50,000 mIU/mL vs. 56,959 mIU/mL, adjusted ratio 0.89, 80% CI 0.79; 1.01). Vaccine Response Rate, defined as a 4-fold rise in antibody concentration from baseline, Geometric Mean Fold-Rise (GMFR) in anti-gE ELISA from baseline, and fold rises in neutralizing antibody were identical or higher for amezosvatein (Figure 1). Amezosvatein demonstrated a clinically superior tolerability profile compared to Shingrix as measured by Grade 2/3 solicited local and systemic adverse events. Grade 2/3 solicited AEs were reported by 7.3% of amezosvatein recipients versus 33.3% of Shingrix recipients. This difference was statistically significant in a post hoc analysis (p< 0.001) (Figure 2). Conclusion Our findings suggest amezosvatein has been shown as efficacious with a potentially better tolerability profile, making it a potentially-attractive alternative for the prevention of herpes zoster. Global Phase 3 trials of amezosvatein are anticipated to begin shortly. Disclosures Lisa R. Shelton, ARNP, Curevo Vaccine: Salary|Curevo Vaccine: Stocks/Bonds (Private Company) Soren Gantt, MD PHD MPH FRCPC, Altona Diagnostics: Grant/Research Support|Curevo Vaccine: Advisor/Consultant|GSK: Advisor/Consultant|GSK: Grant/Research Support|Merck: Advisor/Consultant|Merck: Grant/Research Support|Meridian Biosciences: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Pfizer: Grant/Research Support|VBI: Grant/Research Support Guy De La Rosa, MD, Curevo Vaccine: Employee|Curevo Vaccine: Stocks/Bonds (Private Company) David A. G. Skibinski, PhD, Curevo Vaccine: Salary|Curevo Vaccine: Stocks/Bonds (Private Company) George Simeon, MPH, Curevo Inc.: Board Member|Curevo Inc.: salary|Curevo Inc.: Stocks/Bonds (Private Company) David Miller, BA, Curevo Vaccine: Employee|Curevo Vaccine: Stocks/Bonds (Private Company)
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.010 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".